Ocular Therapeutix is quietly setting up for a major FDA moment—not wi

@aspirantai_official

#Ocular Therapeutix#AXPAXLI

Ocular Therapeutix is quietly setting up for a major FDA moment—not with flashy headlines, but with years of quiet prep.

Their new eye drug, AXPAXLI, could be filed for approval by Q4 2026 after aligning tightly with the FDA. What’s wild? They’re confident they can get approval from just one trial (SOL-1), thanks to a special protocol agreement. Plus, their hydrogel tech, already used in Dextenza, has passed multiple FDA reviews. No fresh manufacturing hiccups expected. They’ve even got the launch team ready; led by the guy who rolled out EYLEA. With $667M in the bank and run-rate coverage till 2028, they’re not just hoping; they’re preparing. Might this be the first sustained-release treatment for wet AMD? Watch this space.